Research programme: fixed-dose combination therapeutics - Daewoong PharmaceuticalAlternative Names: DWJ 1325; DWJ 1330; DWJ 1340
Latest Information Update: 08 Oct 2015
At a glance
- Originator Daewoong Pharmaceutical
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Peptic ulcer
- Research Cough; Hyperlipidaemia